The phase III study, NINJA (JapicCTI-153004), compared nivolumab (PD-1 inhibitor) with chemotherapy (gemcitabine or pegylated liposomal doxorubicin) in patients with platinum-resistant ovarian cancer. This evidence concerns the gene PDCD1 and ovarian cancer.